Prasad Iyer

Professor of Medicine and Chair

Mayo Clinic Arizona
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Multistage study design from marker discovery to validation. Workflow overview of initial marker discovery using WGMS on DNA extracted from endoscopic brushing samples with cross-reference to an archival RRBS dataset from DNA extracted from independent tissue samples, and independent validation comparing paired endoscopic brushings and sponge-on-string samples. EAC, esophageal adenocarcinoma; EM-seq, enzymatic methyl sequencing; methyl-seq, methyl sequencing; WGBS, whole genome bisulfite sequencing.

Year:

2026

ROC curves for MDM performance in paired endoscopic brush and sponge samples. A, AUC analysis demonstrating discrimination of HGD/esophageal adenocarcinoma (EAC) from NDBE using the MDM panel, AS, and the combination in endoscopic brush samples. B, Corresponding AUC analysis showing marker performance in paired available ( Table 1 ) sponge-on-string samples from the same patients.

Year:

2026

Aberrant DNA methylation and copy-number alterations (CNA) drive Barrett’s esophagus progression to esophageal adenocarcinoma; however, their combined utility for early detection is unclear. We aimed to identify and validate methylated DNA markers (MDM) and CNAs to distinguish esophageal adenocarcinoma/high-grade dysplasia (HGD) from nondysplastic Barrett’s esophagus (NDBE). In this multiphase, multicenter study, we discovered and validated MDMs and quantified CNAs utilizing whole-genome methylation sequencing of esophageal brushings. DNA biomarkers identified from discovery were further validated in independent patients with paired esophageal brushing and swallowed capsule sponge samples. MDMs were filtered against a reduced representation bisulfite sequencing dataset obtained from independent tissue samples to advance only concordant candidates. CNA burden was quantified using ichorCNA-derived aneuploidy scores (AS). Two hundred MDMs discovered in HGD ( N = 18) and esophageal adenocarcinoma ( N = 18) versus NDBE brushing samples ( N = 18) were tested in independent samples ( N = 146). A 52-MDM panel achieved a cross-validated AUC of 0.88 [95% confidence interval (CI), 0.82–0.95]; the addition of AS improved discrimination of HGD/esophageal adenocarcinoma from NDBE to 0.91 (95% CI, 0.86–0.97) AUC. At 80% specificity, the combined model detected 93% of esophageal adenocarcinoma and 88% of HGD cases. In paired capsule sponge samples, a 58-MDM panel achieved a cross-validated AUC of 0.77 (95% CI, 0.66–0.88); a combined 58-MDM and AS model achieved AUC 0.80 (95% CI, 0.7–0.9). MDMs and AS discerned HGD/esophageal adenocarcinoma from normal esophagus/NDBE in endoscopic brushing and capsule sponge samples. This approach may improve Barrett’s esophagus surveillance. Prevention Relevance: This study demonstrates that combining epigenetic and genomic biomarkers across minimally invasive sampling methods can accurately distinguish HGD/esophageal adenocarcinoma from nondysplastic Barrett’s esophagus, offering promising, less invasive strategies to improve BE surveillance and enable endoscopic therapy for esophageal adenocarcinoma prevention and treatment.

Year:

2026

Methylation and copy-number profiles in discovery and validation case and control sample sets. For methylation, each row is a marker from the filtered set of 52 MDMs and each column a patient sample. For copy number, each row is a chromosomal arm. Methylation marker levels measured in deciles above the 95th percentile value in NDBE are denoted by the increasing intensity of yellow to red color spectrum. Copy-number analysis shows amplifications (red) or deletions (blue) referent to neutral (white) as estimated by the AS method. NDBE referent to NE (gray, neutral by definition). EAC, esophageal adenocarcinoma.

Year:

2026

Background: Over 20 susceptibility single-nucleotide polymorphisms (SNP) have been identified for esophageal adenocarcinoma (EAC) and its precursor, Barrett esophagus (BE), explaining a small portion of heritability. Methods: Using genetic data from 4,323 BE and 4,116 EAC patients aggregated by international consortia including the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), we conducted a comprehensive transcriptome-wide association study (TWAS) for BE/EAC, leveraging Genotype Tissue Expression (GTEx) gene-expression data from six tissue types of plausible relevance to EAC etiology: mucosa and muscularis from the esophagus, gastroesophageal (GE) junction, stomach, whole blood, and visceral adipose. Two analytical approaches were taken: standard TWAS using the predicted gene expression from local expression quantitative trait loci (eQTL), and set-based SKAT association using selected eQTLs that predict the gene expression. Results: Although the standard approach did not identify significant signals, the eQTL set–based approach identified eight novel associations, three of which were validated in independent external data (eQTL SNP sets for EXOC3 , ZNF641 , and HSP90AA1 ). Conclusions: This study identified novel genetic susceptibility loci for EAC and BE using an eQTL set–based genetic association approach. Impact: This study expanded the pool of genetic susceptibility loci for EAC and BE, suggesting the potential of the eQTL set–based genetic association approach as an alternative method for TWAS analysis.

Year:

2025

Aberrant DNA methylation and copy-number alterations (CNA) drive Barrett’s esophagus progression to esophageal adenocarcinoma; however, their combined utility for early detection is unclear. We aimed to identify and validate methylated DNA markers (MDM) and CNAs to distinguish esophageal adenocarcinoma/high-grade dysplasia (HGD) from nondysplastic Barrett’s esophagus (NDBE). In this multiphase, multicenter study, we discovered and validated MDMs and quantified CNAs utilizing whole-genome methylation sequencing of esophageal brushings. DNA biomarkers identified from discovery were further validated in independent patients with paired esophageal brushing and swallowed capsule sponge samples. MDMs were filtered against a reduced representation bisulfite sequencing dataset obtained from independent tissue samples to advance only concordant candidates. CNA burden was quantified using ichorCNA-derived aneuploidy scores (AS). Two hundred MDMs discovered in HGD (N = 18) and esophageal adenocarcinoma (N = 18) versus NDBE brushing samples (N = 18) were tested in independent samples (N = 146). A 52-MDM panel achieved a cross-validated AUC of 0.88 [95% confidence interval (CI), 0.82–0.95]; the addition of AS improved discrimination of HGD/esophageal adenocarcinoma from NDBE to 0.91 (95% CI, 0.86–0.97) AUC. At 80% specificity, the combined model detected 93% of esophageal adenocarcinoma and 88% of HGD cases. In paired capsule sponge samples, a 58-MDM panel achieved a cross-validated AUC of 0.77 (95% CI, 0.66–0.88); a combined 58-MDM and AS model achieved AUC 0.80 (95% CI, 0.7–0.9). MDMs and AS discerned HGD/esophageal adenocarcinoma from normal esophagus/NDBE in endoscopic brushing and capsule sponge samples. This approach may improve Barrett’s esophagus surveillance. Prevention Relevance: This study demonstrates that combining epigenetic and genomic biomarkers across minimally invasive sampling methods can accurately distinguish HGD/esophageal adenocarcinoma from nondysplastic Barrett’s esophagus, offering promising, less invasive strategies to improve BE surveillance and enable endoscopic therapy for esophageal adenocarcinoma prevention and treatment.

Year:

2025

In this brief review we discuss the potential reasons underlying and follow up of patients who have a positive non-endoscopic swallowable cell collection device+biomarker (such as TFF3) test but no evidence of Barrett’s esophagus on endoscopy. We discuss the potential role of careful examination of the gastroesophageal junction and targeted biopsies of any visible lesions, as well endoscopic follow up in 3-5 years in the absence of any alarm symptoms. Considerations of the use of new technologies such as wide area transepithelial sampling in this situation are also discussed.

Year:

2025

Collaborators (30)

Rebecca C. Fitzgerald

Head of Academic Department

University of Cambridge

UNITED KINGDOM
View details

John Kisiel

Mayo Clinic

UNITED STATES
View details

Claire Palles

Associate Professor

University of Birmingham

UNITED KINGDOM
View details

Ines Gockel

University Hospital Leipzig

GERMANY
View details

Xiaoyu Wang

University of Florida

UNITED STATES
View details

Johannes Schumacher

Philipps-Universität Marburg

GERMANY
View details

Wong-Ho Chow

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Puya Gharahkhani

Team Head, Associate Professor

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Markus Nöthen

Professor, Director

University Hospital Bonn

GERMANY
View details

Thomas Schmidt

Professor of Surgical Oncology / Chief Senior Consultant

Universitätsklinikum Bonn

GERMANY
View details

Sharon B Love

Methodology Lead of Trial Conduct Research

University College London

UNITED KINGDOM
View details

Thomas Vaughan

Professor

University of Washington

UNITED STATES
View details

Ian Tomlinson

University of Edinburgh

UNITED KINGDOM
View details

Lesley Anderson

University of Aberdeen

UNITED KINGDOM
View details

Douglas Mahoney

Assistant Professor

Mayo Clinic

UNITED STATES
View details

John de Caestecker

Honorary Professor

University of Leicester

UNITED KINGDOM
View details

Hans Prenen

Antwerp University Hospital

BELGIUM
View details

Carlos Caldas

Professor

Hebrew University of Jerusalem

ISRAEL
View details

Jesper Lagergren

Professor and Chair of Upper Gastrointestinal Cancer and Honorary Consultant Surgeon

King’s College London

UNITED KINGDOM
View details

David Whiteman

Deputy Director

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Thomas Rösch

Chief of department, Prof. Dr

-

GERMANY
View details

Stuart MacGregor

Professor

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Anna H. Wu

Professor

University of Southern California

UNITED STATES
View details

Matthias Reeh

University Medical Center Hamburg-Eppendorf

GERMANY
View details

Paul Pharoah

Professor of Cancer Epidemiology

Cedars-Sinai Medical Center

UNITED STATES
View details

Marino Venerito

-

GERMANY
View details

Paul Moayyedi

Audrey Campbell Chair of Ulcerative Colitis Research

McMaster University

CANADA
View details

Zhifu Sun

Consultant/Professor

Mayo Clinic Minnesota

UNITED STATES
View details

Janusz Jankowski

Professor

University College London

UNITED KINGDOM
View details

Geoffrey Liu

The M. Qasim Choksi Chair in Lung Cancer Translational Research

University of Toronto

CANADA
View details